The DOI matches its Crossref record.
Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts
Open accessAbstract
We examined a panel of 25 small cell lung cancer (SCLC) cell lines and nude mouse xenografts for expression of the proto-oncogenes c-met and c-kit, and for expression of the corresponding ligands, hepatocyte growth factor (HGF) (also known as scatter factor (SF)), and stem cell factor (SCF), respectively. Expression of mRNA was detected by Northern blotting, and c-met and c-kit protein expression was detected by Western blotting and immunocytochemistry. c-met and c-kit mRNA was expressed in 22 of the examined cell lines or xenografts, and coexpression of the two proto-oncogenes was observed in 20 tumours. Expression of c-met and c-kit protein paralleled in the mRNA expression. HGF/SF mRNA was expressed in two of the examined tumours, and only one of these also expressed the c-met proto-oncogene. SCF mRNA was expressed in 19 of the examined tumours, and in 18 of these coexpression of c-kit and SCF was present. The high percentage of SCLC tumours expressing c-met and c-kit indicates that these proto-oncogenes may have an important function in this disease. The rare coexpression of c-met and HGF/SF is evidence that an autocrine regulatory pathway is not present for this receptor/ligand system in SCLC, while the frequent coexpression of c-kit and SCF indicates that this receptor/ligand system may have an autocrine function in SCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
van Meerbeeck, J. P., Fennell, D. A., & De Ruysscher, D. K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,237
MicroRNAs in Development and Disease
Sayed, D., & Abdellatif, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00006.2010 · Cited by 1,078
Jackman, D. M., & Johnson, B. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67569-1 · Cited by 503
Sher, T., Dy, G. K., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.3.355 · Cited by 498
Kalemkerian, G. P., Akerley, W., Bogner, P., Borghaei, H., Chow, L. Q., Downey, R. J., Gandhi, L., Ganti, A. K. P., Govindan, R., Grecula, J. C., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0011 · Cited by 436
Maulik, G., Shrikhande, A., Kijima, T., Ma, P. C., Morrison, P. T., & Salgia, R. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00029-6 · Cited by 391
Tumor–platelet interaction in solid tumors
Buergy, D., Wenz, F., Groden, C., & Brockmann, M. A. (2012) · International Journal of Cancer · doi:10.1002/ijc.27441 · Cited by 352
Rossi, G., Cavazza, A., Marchioni, A., Longo, L., Migaldi, M., Sartori, G., Bigiani, N., Schirosi, L., Casali, C., Morandi, U., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8233 · Cited by 303
Protein tyrosine kinases and cancer
Kolibaba, K. S., & Druker, B. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00022-x · Cited by 291
Progress in understanding the molecular pathogenesis of human lung cancer
Sekido, Y., Fong, K. M., & Minna, J. D. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00010-9 · Cited by 290
Hepatocyte growth factor/scatter factor—Met signaling in tumorigenicity and invasion/metastasis
Jeffers, M., Rong, S., & Vande Woude, G. F. (1996) · Journal of Molecular Medicine · doi:10.1007/bf00204976 · Cited by 288
Pharmacology of imatinib (STI571)
Buchdunger, E., O'Reilley, T., & Wood, J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80600-1 · Cited by 269
Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer
Jiang, W. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(98)00019-5 · Cited by 264
Metadata
- Authors
- Rygaard, K., Nakamura, T., & Spang-Thomsen, M.
- Venue
- British Journal of Cancer
- Published
- 1993-01
- Volume
- 67
- Issue
- 1
- Pages
- 37-46
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2073700431
- Cited by
- 170
- References
- 0
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.